Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Share-based Compensation of $3.2 million for Q1 2026, down 50.71% year-over-year from $6.5 million in Q1 2025, and up 118.16% quarter-over-quarter from -$17.6 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 50.71% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at -$3.3 million (up 48.18% YoY), while the FY2023 annual figure was $54.8 million, changed N/A from the prior year.
- Share-based Compensation for Q1 2026 stood at $3.2 million, up from -$17.6 million in the prior quarter.
- The five-year high for Share-based Compensation was $16.8 million in Q2 2022, with the low at -$37.2 million in Q4 2022.
- The 5-year median for Share-based Compensation is $10.3 million (2022), against an average of $3.4 million.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation soared 137.28% in 2023, then tumbled 358.69% in 2024.
- Zentalis Pharmaceuticals' Share-based Compensation stood at -$37.2 million in 2022, then jumped by 137.28% to $13.9 million in 2023, then plunged by 358.69% to -$35.9 million in 2024, then soared by 50.98% to -$17.6 million in 2025, then jumped by 118.16% to $3.2 million in 2026.
- Business Quant data shows ZNTL's Share-based Compensation at $3.2 million in Q1 2026, -$17.6 million in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.22 Mn |
| Jun 30, 2026 | 3.22 Mn |
| Mar 31, 2026 | 3.20 Mn |
| Mar 31, 2026 | 3.20 Mn |
| Dec 31, 2025 | -17.60 Mn |
| Dec 31, 2025 | -17.60 Mn |
| Sep 30, 2025 | 4.83 Mn |
| Sep 30, 2025 | 4.83 Mn |
| Jun 30, 2025 | 6.29 Mn |
| Jun 30, 2025 | 6.29 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | -35.91 Mn |
| Dec 31, 2024 | -35.91 Mn |
| Sep 30, 2024 | 10.36 Mn |
| Sep 30, 2024 | 10.36 Mn |
| Jun 30, 2024 | 12.71 Mn |
| Jun 30, 2024 | 12.71 Mn |
| Mar 31, 2024 | 12.83 Mn |
| Mar 31, 2024 | 12.83 Mn |